Purpose: This study investigates the efficacy of 3 Tesla magnetic resonance (MR) microimaging for characterisation of primary melanoma. Technologies currently in use for non-invasive characterization of melanoma (confocal microscopy, optical coherence tomography, or high frequency ultrasound) are limited by restricted penetration depth. In contrast, MR microimaging can determine the full depth of all tumors.

CD10 may be a useful adjunct in assessing malignancy in mammary fibroepithelial lesions.

The authors provide an update on a previously reported patient with in-transit metastatic melanoma of the scalp treated with topical diphencyprone (DPCP). Molecular studies implicate the thymus-derived TH17 lymphocyte subset in a remarkable immunotherapeutic regression. The authors performed RT-PCR of total RNA from paraffin-embedded tissue before and after treatment with DPCP. Before treatment with DPCP, the authors found elevated expression of IL 17C/D/E/F; after treatment there was no detectable expression. Conversely, increased expression of PLZF/CD27 and CTLA4 was seen after treatment with no expression before treatment. No expression of IL17A/B, CD7, RORgTand FoxP3 were before or after treatment. Conclusions are limited to only the time samples were obtained. Remarkable regression of an in-transit metastatic melanoma treated with the immunomodulatory agent DPCP showed gain and loss of gene expression of the TH17 pathway. Further study of this pathway from NK to NK-T to TH7 and TH1 cells both with and without accessory or dendritic cells will improve understanding of contact sensitizers as topical immunomodulators.